SYNTHETIC BIOPSY
Live / Registered — Registered (as of 13 Feb 2024)
What this means for you
Registered since 13 Feb 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90700876
- Registration number
- 7305215
- Mark type
- Stylized text
- Filed
- 10 May 2021
- Published for opposition
- 26 Jul 2022
- Registered
- 13 Feb 2024
- Attorney of record
- Ted D. Karr
Goods and services
- Class 005 — Pharmaceuticals: Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for prevention of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for detection of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for localization of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for therapy of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for prevention of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for detection of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for localization of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for therapy of diseases, namely, cancer or other diseases related to genetic dysregulation
- Class 044 — Medical, beauty and agricultural services: Medical services for prevention of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for detection of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for localization of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for therapy of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for prevention of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services; Medical services for detection of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services; Medical services for localization of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services; Medical services for therapy of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services
Owner
- Earli Inc., South San Francisco, CA, US
- Earli Inc., South San Francisco, CA, US
- Earli Inc., South San Francisco, CA, US
Prosecution history
- 13 Feb 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 13 Feb 2024 — REGISTERED-PRINCIPAL REGISTER
- 10 Jan 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 09 Jan 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 09 Jan 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 09 Jan 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 09 Jan 2024 — ASSIGNED TO LIE
- 15 Aug 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 07 Jul 2023 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 07 Jul 2023 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 10 Apr 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 10 Apr 2023 — NON-FINAL ACTION E-MAILED
- 10 Apr 2023 — SU - NON-FINAL ACTION - WRITTEN
- 24 Feb 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 01 Feb 2023 — USE AMENDMENT FILED